The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

The availability of suzetrigine may represent a critical step in addressing the nation’s pain management crisis. While ...

BB Biotech reported a net loss of CHF 241 mn for Q1 2025. The share price closed the quarter at a 14.1% discount to NAV, broadly in line with year-end 2024. The share price performance for the quarter ...

UMass Lowell Recognized as Top Research Institution with R1 Classification Read More ⁠ ...

What should investors who are experiencing Nasdaq market whiplash do now? I think buying three Nasdaq stocks hand over fist and holding them for decades is a smart move.

Heading into 2025, an even bigger game changer for the company may be Journavx, approved in January by the FDA as the first oral non-opioid painkiller in its class. Journavx taps into a massive ...

As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, ...